NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its primary and a key secondary endpoint in the phase III NIMBLE trial of ...
Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results